Jeremy R Chapman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10576764/publications.pdf

Version: 2024-02-01

162 papers	13,305 citations	34105 52 h-index	22832 112 g-index
165 all docs	165 docs citations	165 times ranked	10408 citing authors

#	Article	IF	Citations
1	Factors Associated With Advanced Colorectal Neoplasia in Patients With CKD. American Journal of Kidney Diseases, 2022, 79, 549-560.	1.9	8
2	Nonutilization of Kidneys From Donors After Circulatory Determinant of Death. Transplantation Direct, 2022, 8, e1331.	1.6	2
3	Donor-derived Diseaseâ€"Who to Notify?. Transplantation, 2021, 105, 1909-1910.	1.0	1
4	The IDEAL trial in Australia and New Zealand: clinical and economic impact. Nephrology Dialysis Transplantation, 2021, 37, 168-174.	0.7	1
5	Integrative Analysis of Prognostic Biomarkers for Acute Rejection in Kidney Transplant Recipients. Transplantation, 2021, 105, 1225-1237.	1.0	7
6	Principles and strategies for involving patients in research in chronic kidney disease: report from national workshops. Nephrology Dialysis Transplantation, 2020, 35, 1585-1594.	0.7	14
7	The Pathophysiology and Impact of Inflammation in Nonscarred Renal Interstitium: The Banff i Lesion. Transplantation, 2020, 104, 835-846.	1.0	5
8	Health-Related Quality of Life in People Across the Spectrum of CKD. Kidney International Reports, 2020, 5, 2264-2274.	0.8	25
9	Relative survival and quality of life benefits of pancreasâ€"kidney transplantation, deceased kidney transplantation and dialysis in type 1 diabetes mellitusâ€"a probabilistic simulation model. Transplant International, 2020, 33, 1393-1404.	1.6	15
10	Recruitment and retention in clinical trials in chronic kidney disease: report from national workshops with patients, caregivers and health professionals. Nephrology Dialysis Transplantation, 2020, 35, 755-764.	0.7	19
11	Adenine Phosphoribosyltransferase Deficiency: A Potentially Reversible Cause of CKD. Kidney International Reports, 2019, 4, 1161-1170.	0.8	12
12	One-Time Fecal Immunochemical Screening for Advanced Colorectal Neoplasia in Patients with CKD (DETECT Study). Journal of the American Society of Nephrology: JASN, 2019, 30, 1061-1072.	6.1	19
13	Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant. Journal of the American Society of Nephrology: JASN, 2019, 30, 471-480.	6.1	81
14	The Recipient of a Renal Transplant. , 2019, , 51-68.		0
15	Informative for Decision Making? The Spectrum and Consistency of Outcomes After Living Kidney Donation Reported in Trials and Observational Studies. Transplantation, 2019, 103, 284-290.	1.0	8
16	Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. The Cochrane Library, 2019, 12, CD004290.	2.8	17
17	The clinical and pathological significance of borderline T cellâ€"mediated rejection. American Journal of Transplantation, 2019, 19, 1452-1463.	4.7	75
18	Cliniciansâ€™ attitudes and approaches to evaluating the potential living kidney donorâ€recipient relationship: An interview study. Nephrology, 2019, 24, 252-262.	1.6	6

#	Article	IF	Citations
19	Does tubulitis without interstitial inflammation represent borderline acute T cell mediated rejection?. American Journal of Transplantation, 2019, 19, 132-144.	4.7	33
20	Survival and Quality of Life Impact of a Risk-based Allocation Algorithm for Deceased Donor Kidney Transplantation. Transplantation, 2018, 102, 1530-1537.	1.0	8
21	Renal transplant outcomes and de novo donor-specific anti-human leukocyte antigen antibodies: a systematic review. Nephrology Dialysis Transplantation, 2018, 33, 1472-1480.	0.7	24
22	Seeking to Close the Loopholes in Transplant Tourism and Organ Trafficking. Transplantation, 2018, 102, 11-12.	1.0	4
23	The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: The Banff i-IFTA lesion. American Journal of Transplantation, 2018, 18, 364-376.	4.7	113
24	Kidney donation and transplantation in Australia: more than a supply and demand equation. Medical Journal of Australia, 2018, 209, 242-243.	1.7	9
25	Range and Consistency of Outcomes Reported in Randomized Trials Conducted in Kidney Transplant Recipients: A Systematic Review. Transplantation, 2018, 102, 2065-2071.	1.0	26
26	Cancer in kidney transplant recipients. Nature Reviews Nephrology, 2018, 14, 508-520.	9.6	137
27	Identifying Outcomes that Are Important to Living Kidney Donors. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 916-926.	4.5	35
28	Patient experiences of training and transition to home haemodialysis: A mixed-methods study. Nephrology, 2017, 22, 631-641.	1.6	22
29	Perspectives of Older Kidney Transplant Recipients on Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 443-453.	4.5	47
30	Research priority setting in organ transplantation: a systematic review. Transplant International, 2017, 30, 327-343.	1.6	30
31	Setting the limit for living kidney donationâ€"how big is too big?. Kidney International, 2017, 91, 534-536.	5.2	2
32	Clearance of BK Virus Nephropathy by Combination Antiviral Therapy With Intravenous Immunoglobulin. Transplantation Direct, 2017, 3, e142.	1.6	48
33	The Lived Experience of â€œBeing Evaluatedâ€•for Organ Donation. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1852-1861.	4.5	25
34	Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. The Cochrane Library, 2017, 2017, CD004756.	2.8	38
35	Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation. Transplantation, 2017, 101, 1875-1886.	1.0	68
36	Expectations and Experiences of Follow-up and Self-Care After Living Kidney Donation. Transplantation, 2017, 101, 2627-2635.	1.0	12

#	Article	IF	Citations
37	Progress in Transplantation: Will It Be Achieved in Big Steps or by Marginal Gains?. American Journal of Kidney Diseases, 2017, 69, 287-295.	1.9	15
38	Donor and Recipient Views on Their Relationship in Living Kidney Donation: Thematic Synthesis of Qualitative Studies. American Journal of Kidney Diseases, 2017, 69, 602-616.	1.9	28
39	Cytomegalovirus and cancer after kidney transplantation: Role of the human leukocyte antigen system?. Transplant Infectious Disease, 2017, 19, e12631.	1.7	5
40	Standardized Outcomes in Nephrology-Transplantation: A Global Initiative to Develop a Core Outcome Set for Trials in Kidney Transplantation. Transplantation Direct, 2016, 2, e79.	1.6	30
41	HLA-DQ Mismatches and Rejection in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 875-883.	4.5	71
42	Buyer beware transplantation. Kidney International, 2016, 89, 983-985.	5.2	0
43	Care of Transplant Recipients in Primary Practice. Transplantation, 2016, 100, 474-476.	1.0	7
44	â€˜I feel stronger and younger all the timeâ€™â€”perspectives of elderly kidney transplant recipients: thematic synthesis of qualitative research. Nephrology Dialysis Transplantation, 2016, 31, 1531-1540.	0.7	25
45	Cancer in patients with inherited ciliopathies: polycystic kidney disease. Lancet Oncology, The, 2016, 17, 1343-1345.	10.7	2
46	Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study. Lancet, The, 2016, 388, 983-993.	13.7	148
47	The Association Between Broad Antigen HLA Mismatches, Eplet HLA Mismatches and Acute Rejection After Kidney Transplantation. Transplantation Direct, 2016, 2, e120.	1.6	29
48	Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology. Transplantation, 2016, 100, 1723-1731.	1.0	136
49	Maternal compared with paternal donor kidneys are associated with poorer graft outcomes after kidney transplantation. Kidney International, 2016, 89, 659-665.	5.2	7
50	Mortality among Younger and Older Recipients of Kidney Transplants from Expanded Criteria Donors Compared with Standard Criteria Donors. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 128-136.	4.5	43
51	Organ Transplantation in China. Transplantation, 2015, 99, 1312-1313.	1.0	8
52	Peak Panel Reactive Antibody, Cancer, Graft, and Patient Outcomes in Kidney Transplant Recipients. Transplantation, 2015, 99, 1043-1050.	1.0	53
53	The Relative Benefits and Costs of Solid Phase Bead Technology to Detect Preformed Donor Specific Antihuman Leukocyte Antigen Antibodies in Determining Suitability for Kidney Transplantation. Transplantation, 2015, 99, 957-964.	1.0	11
54	â€˜Suspended in a paradoxâ€™-patient attitudes to wait-listing for kidney transplantation: systematic review and thematic synthesis of qualitative studies. Transplant International, 2015, 28, 771-787.	1.6	44

#	Article	IF	Citations
55	Clinical Utility of Urinary Cytology to Detect BK Viral Nephropathy. Transplantation, 2015, 99, 1715-1722.	1.0	31
56	Cancer-Specific and All-Cause Mortality in Kidney Transplant Recipients With and Without Previous Cancer. Transplantation, 2015, 99, 2586-2592.	1.0	46
57	Research Priorities in CKD: Report of a National Workshop Conducted in Australia. American Journal of Kidney Diseases, 2015, 66, 212-222.	1.9	73
58	The Expectations and Attitudes of Patients With Chronic Kidney Disease Toward Living Kidney Donor Transplantation. Transplantation, 2015, 99, 540-554.	1.0	51
59	Marginal kidneys for transplantation. BMJ, The, 2015, 351, h3856.	6.0	3
60	Renal transplantation: better fat than thin. Journal of Surgical Research, 2015, 194, 644-652.	1.6	19
61	Cumulative Doses of T-Cell Depleting Antibody and Cancer Risk after Kidney Transplantation. PLoS ONE, 2015, 10, e0139479.	2.5	5
62	Professor Bruce Hall and the ABC. Medical Journal of Australia, 2014, 201, 322-322.	1.7	0
63	Death from cancer: a sobering truth for patients with kidney transplants. Kidney International, 2014, 85, 1262-1264.	5.2	28
64	Belatacept for kidney transplant recipients. The Cochrane Library, 2014, 2014, CD010699.	2.8	82
65	The Risk of Cancer in Recipients of Living-Donor, Standard and Expanded Criteria Deceased Donor Kidney Transplants. Transplantation, 2014, 98, 1286-1293.	1.0	31
66	Public Attitudes and Beliefs About Living Kidney Donation. Transplantation, 2014, 97, 977-985.	1.0	17
67	How is Health Economics Relevant to Transplant Clinicians?. Transplantation, 2014, 98, 124-130.	1.0	6
68	Perspectives of Transplant Physicians and Surgeons on Reimbursement, Compensation, and Incentives for LivingÂKidney Donors. American Journal of Kidney Diseases, 2014, 64, 622-632.	1.9	29
69	Reduced Estimated GFR and Cancer Mortality. American Journal of Kidney Diseases, 2014, 63, 23-30.	1.9	121
70	Acute Rejection, T-Cellâ€“Depleting Antibodies, and Cancer After Transplantation. Transplantation, 2014, 97, 817-825.	1.0	56
71	The Recipient of a Kidney Transplant. , 2014, , 54-71.		0
72	Motivations, Experiences, and Perspectives of Bone Marrow and Peripheral Blood Stem Cell Donors: Thematic Synthesis of Qualitative Studies. Biology of Blood and Marrow Transplantation, 2013, 19, 1046-1058.	2.0	46

#	Article	IF	Citations
73	Post-transplant Pneumocystis jirovecii pneumoniaâ€"a re-emerged public health problem?. Kidney International, 2013, 84, 240-243.	5.2	50
74	Health benefits and costs of screening for colorectal cancer in people on dialysis or who have received a kidney transplant. Nephrology Dialysis Transplantation, 2013, 28, 917-926.	0.7	18
75	Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation. Transplantation, 2013, 95, 19-47.	1.0	679
76	Cancer in the Transplant Recipient. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a015677-a015677.	6.2	221
77	Are Nonesterified Fatty Acids Protective in Chronic Allograft Nephropathy?. Transplantation, 2013, 95, 1313-1314.	1.0	0
78	Public Awareness and Attitudes to Living Organ Donation. Transplantation, 2013, 96, 429-437.	1.0	45
79	Time on Dialysis and Cancer Risk After Kidney Transplantation. Transplantation, 2013, 95, 114-121.	1.0	51
80	China and the organ trade. Medical Journal of Australia, 2013, 199, 728-728.	1.7	0
81	Autosomal dominant polycystic kidney disease (ADPKD) is associated with coronary arterial dilatation in end-stage renal failure patients. CKJ: Clinical Kidney Journal, 2012, 5, 41-43.	2.9	1
82	Do protocol transplant biopsies improve kidney transplant outcomes?. Current Opinion in Nephrology and Hypertension, 2012, 21, 580-586.	2.0	25
83	The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation, 2012, 27, 3337-3344.	0.7	31
84	Reply to â€œReview of Living Kidney Donor Guidelines is Out of Date Before Publicationâ€•. Transplantation, 2012, 93, e18-e19.	1.0	0
85	Mycophenolate Versus Azathioprine for Kidney Transplantation. Transplantation, 2012, 94, 152-158.	1.0	49
86	Despite the Best Intentions Cancer Is Transmissible by Transplantation. Transplantation, 2012, 94, 1185-1186.	1.0	2
87	Clinical Practice Guidelines on Wait-Listing for Kidney Transplantation. Transplantation, 2012, 94, 703-713.	1.0	115
88	Balancing sensitivity and specificity - unfolding crossmatch biology in renal transplantation*. Transplant International, 2012, 25, 1129-1130.	1.6	0
89	Knowledge, beliefs and attitudes of kidney transplant recipients regarding their risk of cancer. Nephrology, 2012, 17, 300-306.	1.6	33
90	The Motivations and Experiences of Living Kidney Donors: A Thematic Synthesis. American Journal of Kidney Diseases, 2012, 60, 15-26.	1.9	123

#	Article	IF	Citations
91	The experiences of commercial kidney donors: thematic synthesis of qualitative research. Transplant International, 2012, 25, 1138-1149.	1.6	49
92	Comparative Survival and Economic Benefits of Deceased Donor Kidney Transplantation and Dialysis in People with Varying Ages and Co-Morbidities. PLoS ONE, 2012, 7, e29591.	2.5	158
93	The consequences of successful transplantation. Lancet, The, 2011, 378, 1357-1359.	13.7	13
94	Screening and Follow-Up of Living Kidney Donors: A Systematic Review of Clinical Practice Guidelines. Transplantation, 2011, 92, 962-972.	1.0	97
95	Test performance of faecal occult blood testing for the detection of bowel cancer in people with chronic kidney disease (DETECT) protocol. BMC Public Health, 2011, 11, 516.	2.9	6
96	Screening for renal cancer in recipients of kidney transplants. Nephrology Dialysis Transplantation, 2011, 26, 1729-1739.	0.7	43
97	Transcriptome Changes of Chronic Tubulointerstitial Damage in Early Kidney Transplantation. Transplantation, 2010, 89, 537-547.	1.0	27
98	The KDIGO Clinical Practice Guidelines for the Care of Kidney Transplant Recipients. Transplantation, 2010, 89, 644-645.	1.0	61
99	Why Do Patients Develop Proteinuria With Sirolimus? Do We Have the Answer?. American Journal of Kidney Diseases, 2010, 55, 213-216.	1.9	14
100	KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney International, 2010, 77, 299-311.	5.2	675
101	Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ: British Medical Journal, 2010, 340, c570-c570.	2.3	149
102	Not that day â€¦. Medical Journal of Australia, 2009, 191, 613-614.	1.7	0
103	The pattern of excess cancer in dialysis and transplantation. Nephrology Dialysis Transplantation, 2009, 24, 3225-3231.	0.7	174
104	Reported cancer screening practices of nephrologists: results from a national survey. Nephrology Dialysis Transplantation, 2009, 24, 2136-2143.	0.7	21
105	Association of CKD and Cancer Risk in Older People. Journal of the American Society of Nephrology: JASN, 2009, 20, 1341-1350.	6.1	251
106	Immunosuppression and Other Risk Factors for Lip Cancer after Kidney Transplantation. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 561-569.	2.5	73
107	Chronic allograft nephropathy â€“ a clinical syndrome: early detection and the potential role of proliferation signal inhibitors. Clinical Transplantation, 2009, 23, 769-777.	1.6	18
108	Cutaneous Melanoma Is Related to Immune Suppression in Kidney Transplant Recipients. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2297-2303.	2.5	66

#	Article	IF	Citations
109	The Health and Economic Impact of Cervical Cancer Screening and Human Papillomavirus Vaccination in Kidney Transplant Recipients. Transplantation, 2009, 87, 1078-1091.	1.0	39
110	Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood, 2009, 114, 630-637.	1.4	115
111	Management Guidelines Peritransplantation. , 2009, , 341-363.		0
112	Cost-Effectiveness of Breast Cancer Screening in Women on Dialysis. American Journal of Kidney Diseases, 2008, 52, 916-929.	1.9	25
113	Cancers after renal transplantation. Transplantation Reviews, 2008, 22, 141-149.	2.9	90
114	Epithelial-to-Mesenchymal Transition in Early Transplant Tubulointerstitial Damage. Journal of the American Society of Nephrology: JASN, 2008, 19, 1571-1583.	6.1	47
115	Chronic allograft nephropathy--clinical guidance for early detection and early intervention strategies. Nephrology Dialysis Transplantation, 2008, 23, 2467-2473.	0.7	20
116	How can we achieve global equity in provision of renal replacement therapy?. Bulletin of the World Health Organization, 2008, 86, 229-237.	3.3	230
117	Cancer Screening in Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, S87-S100.	4.5	94
118	Cost-Effectiveness of Colorectal Cancer Screening in Renal Transplant Recipients. Transplantation, 2008, 85, 532-541.	1.0	46
119	Individualization of immunosuppression: concepts and rationale. Current Opinion in Organ Transplantation, 2008, 13, 604-608.	1.6	36
120	Introduction: Targets for Improving Outcomes in Renal Allografts Transplanted During the Next Ten Years. Transplantation, 2008, 85, S1-S2.	1.0	1
121	The Recipient of a Renal Transplant. , 2008, , 48-63.		1
122	Increased Incidence of Squamous Cell Carcinoma of Eye After Kidney Transplantation. Journal of the National Cancer Institute, 2007, 99, 1340-1342.	6.3	35
123	Cancer Incidence Before and After Kidney Transplantation. JAMA - Journal of the American Medical Association, 2006, 296, 2823.	7.4	953
124	Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. , 2006, , CD004756.		21
125	Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. The Cochrane Library, 2006, , CD004290.	2.8	58
126	Not All Donors Are Equal. Transplantation, 2006, 81, 976-977.	1.0	1

#	Article	IF	Citations
127	Target of Rapamycin Inhibitors (Sirolimus and Everolimus) for Primary Immunosuppression of Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Trials. Transplantation, 2006, 81, 1234-1248.	1.0	305
128	Monoclonal and Polyclonal Antibody Therapy for Treating Acute Rejection in Kidney Transplant Recipients: A Systematic Review of Randomized Trial Data. Transplantation, 2006, 81, 953-965.	1.0	71
129	Chronic Allograft Nephropathy: Current Concepts and Future Directions. Transplantation, 2006, 81, 643-654.	1.0	294
130	Treatment of Subclinical Rejection Diagnosed by Protocol Biopsy of Kidney Transplants. Transplantation, 2006, 82, 36-42.	1.0	97
131	Nephrotoxicity of ciclosporin A: short-term gain, long-term pain?. Nephrology Dialysis Transplantation, 2006, 21, 2060-2063.	0.7	39
132	Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. The Cochrane Library, 2005, , CD003961.	2.8	144
133	Commentary: Harmonizing the Regulators. Transplantation, 2005, 79, 638.	1.0	0
134	Longitudinal analysis of chronic allograft nephropathy: Clinicopathologic correlations. Kidney International, 2005, 68, S108-S112.	5.2	45
135	Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ: British Medical Journal, 2005, 331, 810.	2.3	482
136	Chronic Renal Allograft Dysfunction. Journal of the American Society of Nephrology: JASN, 2005, 16, 3015-3026.	6.1	382
137	Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials1. Transplantation, 2004, 77, 166-176.	1.0	208
138	Evolution and Pathophysiology of Renal-Transplant Glomerulosclerosis. Transplantation, 2004, 78, 461-468.	1.0	63
139	Delta Analysis of Posttransplantation Tubulointerstitial Damage. Transplantation, 2004, 78, 434-441.	1.0	102
140	Compliance: the patient, the doctor, and the medication?. Transplantation, 2004, 77, 782-786.	1.0	56
141	Calcineurin Inhibitor Nephrotoxicity: Longitudinal Assessment by Protocol Histology. Transplantation, 2004, 78, 557-565.	1.0	419
142	Natural History, Risk Factors, and Impact of Subclinical Rejection in Kidney Transplantation. Transplantation, 2004, 78, 242-249.	1.0	227
143	ORAL CYCLOSPORINE BUT NOT TACROLIMUS REDUCES RENAL TRANSPLANT BLOOD FLOW. Transplantation, 2004, 77, 1457-1459.	1.0	69
144	Interleukin 2 receptor antagonists for kidney transplant recipients. , 2004, , CD003897.		21

#	Article	IF	Citations
145	The Natural History of Chronic Allograft Nephropathy. New England Journal of Medicine, 2003, 349, 2326-2333.	27.0	1,748
146	Detection of chronic allograft nephropathy by quantitative doppler imaging. Transplantation, 2002, 74, 90-96.	1.0	26
147	EFFECT OF HISTOLOGICAL DAMAGE ON LONG-TERM KIDNEY TRANSPLANT OUTCOME. Transplantation, 2001, 71, 515-523.	1.0	236
148	A DIFFERENT VIEW OF SENSITIZATION AFTER RENAL TRANSPLANT REJECTION?. Transplantation, 2001, 71, 825-826.	1.0	1
149	Induction of Allogeneic Islet Tolerance in a Large-Animal Model. Cell Transplantation, 2000, 9, 877-887.	2.5	14
150	POSTTRANSPLANT CATARACT: LESSONS FROM KIDNEY-PANCREAS TRANSPLANTATION. Transplantation, 2000, 69, 1108-1114.	1.0	30
151	Diabetic retinopathy after combined kidneyâ€“pancreas transplantation. Clinical Transplantation, 1999, 13, 356-362.	1.6	85
152	Mercaptoacetyltriglycine diuretic renography and output efficiency measurement in renal transplant patients. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 152-154.	6.4	7
153	Simultaneous pancreas and kidney transplantation: a review of outcome from a single center. Hong Kong Journal of Nephrology, 1999, 1, 11-17.	0.0	0
154	PREDICTORS OF RENAL TRANSPLANT HISTOLOGY AT THREE MONTHS. Transplantation, 1999, 67, 1222-1230.	1.0	111
155	Successful obstetric outcome after simultaneous pancreas and kidney transplantation. Medical Journal of Australia, 1999, 170, 368-370.	1.7	10
156	DIABETIC NEUROPATHY AFTER PANCREAS TRANSPLANTATION: DETERMINANTS OF RECOVERY. Transplantation, 1997, 63, 830-838.	1.0	97
157	Assessment of renal function after kidney transplantation. Transplantation Reviews, 1996, 10, 138-149.	2.9	4
158	The potential role of xenogeneic antigenâ€presenting cells in Tâ€cell coâ€stimulation. Xenotransplantation, 1996, 3, 141-148.	2.8	10
159	CLINICAL DETERMINANTS OF GLUCOSE HOMEOSTASIS AFTER PANCREAS TRANSPLANTATION. Transplantation, 1996, 61, 1705-1711.	1.0	18
160	PREDICTING GLOMERULAR FILTRATION RATE AFTER KIDNEY TRANSPLANTATION. Transplantation, 1995, 59, 1683-1689.	1.0	263
161	DIAGNOSTIC UTILITY OF WHOLE BLOOD CYCLOSPORINE MEASUREMENTS IN RENAL TRANSPLANTATION USING TRIPLE THERAPY. Transplantation, 1994, 58, 989-996.	1.0	53
162	CHARACTERIZATION OF LYMPHOCYTOTOXIC ANTIBODIES CAUSING A POSITIVE CROSSMATCH IN RENAL TRANSPLANTATION. Transplantation, 1989, 48, 953-958.	1.0	111